Regeneron Pharmaceuticals' Net Cash Flow rose 2783.01% to $610.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $634.4 million, marking a year-over-year increase of 35570.33%. This contributed to the annual value of $634.4 million for FY2025, which is 35570.33% up from last year.
According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Net Cash Flow is $610.9 million, which was up 2783.01% from $497.9 million recorded in Q3 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Net Cash Flow peaked at $1.4 billion during Q3 2021, and registered a low of -$2.0 billion during Q2 2023.
Over the past 5 years, Regeneron Pharmaceuticals' median Net Cash Flow value was $153.4 million (recorded in 2022), while the average stood at $45.9 million.
Per our database at Business Quant, Regeneron Pharmaceuticals' Net Cash Flow plummeted by 410546.56% in 2023 and then skyrocketed by 57325.49% in 2025.
Regeneron Pharmaceuticals' Net Cash Flow (Quarter) stood at -$546.8 million in 2021, then rose by 29.52% to -$385.4 million in 2022, then surged by 249.82% to $577.4 million in 2023, then dropped by 17.23% to $477.9 million in 2024, then rose by 27.83% to $610.9 million in 2025.
Its last three reported values are $610.9 million in Q4 2025, $497.9 million for Q3 2025, and -$1.1 billion during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value